We accelerate access to affordable and innovative medicines because Good Health Can’t Wait.
Promises
Principles
Empathy
We understand the needs of our patients
and partners better than others.
Dynamism
We solve challenges that only a few
can, and do this with agility.
Values
In pursuit of providing affordable and innovative medicines for healthier lives, we will create an environment of innovation and learning while continuously reaching for higher levels of excellence
INTEGRITY AND TRANSPARENCY
We will uphold the highest standards of integrity and transparency in all our transactions.
SAFETY
We are committed to providing safe working environments through continuous improvements in our infrastructure, work practices and behaviours.
QUALITY
We are dedicated to designing quality into our products and processes to delight our stakeholders.
PRODUCTIVITY
We strive to achieve more with less through a culture of innovation, continuous improvement and sustained focus on elimination of waste.
RESPECT FOR THE INDIVIDUAL
We are committed to creating a work environment that encourages diverse perspectives and upholds the dignity of work and of individuals.
COLLABORATION AND TEAMWORK
We will leverage expertise and resources from across our global network to create greater value for our stakeholders.
SUSTAINABILITY
We will create value for our stakeholders in a manner that respects our natural environment and serves the best interests of the communities in which we live and work.
Views from the top
Since 1999, Anjum Swaroop, our Chief IP Counsel, has been enabling Dr. Reddy’s to take great strides as a responsible multinational pharmaceutical company. A company veteran with a galaxy of experience and a fun, challenging career, Anjum is a passionate advocate of IP as a way of developing a sustainable business as well as addressing the need for affordable, accessible medicines as quickly as possible. “Innovation sometimes requires one to diverge from conventional strategy and pursue new and different paths,” she says.
Adding women’s health products to our U.S. portfolio
Pleased to announce that we have acquired the MenoLabs® portfolio of women’s health and dietary supplements brands in the U.S.
Creating role models to lead the way to a smarter world
We are gearing up to be future-ready and transform our culture and capability, product quality, process robustness, efficiency and productivity.
Our constant endeavour – Patients first!
Pleased to share that we have entered into a definitive agreement with Nestlé India Limited to form a joint venture company that will bring together the well-known global range of nutritional health solutions as well as vitamin, minerals, herbals and supplements of Nestlé Health Science (NHSc) with the strong and established commercial strengths of Dr. Reddy’s in India and other agreed territories.
“It was a dream. It was not a plan on the drawing board, no. But it was a dream.”
Scientist, entrepreneur and philanthropist Dr. Kallam Anji Reddy is renowned for his path-breaking contributions to making medicines affordable for patients worldwide. He was extremely passionate about drug discovery, was among the pioneers of the active pharmaceutical ingredients (API) industry in India.
Born in Tadepalli village in Andhra Pradesh, India, to a well-to-do farming family, Dr. Anji Reddy grew up watching his father make herbal pills and distribute them free of charge to those in need. Medicine was in his blood, as was a sense of public service. He was also committed to deep science and innovation, which is reflected in Dr. Reddy’s Laboratories’ legacy as well as its progressive approach to business.
Having completed his B.Sc. Tech degree at the University Department of Chemical Technology, Mumbai, Dr. Anji Reddy earned a doctorate in Chemical Engineering from the National Chemical Laboratory, Pune. He then worked for six years at the state-owned Indian Drugs and Pharmaceuticals Ltd (IDPL), an experience that stoked his entrepreneurial ambitions.
In 1973, Dr. Anji Reddy left IDPL, and over the course of the next decade, co-founded two bulk drug manufacturing ventures. Then, in 1984, he collaborated with two technocrat-entrepreneurs to establish Dr. Reddy’s Laboratories and Cheminor Drugs, another bulk drug manufacturing company.
From the outset, he realised that if medicines had to serve their purpose, they had to be affordable and accessible. Dr. Anji Reddy envisioned bringing molecules to India at a price the common man can afford.
But this was not the only way by which he helped people. From supporting a hospital for the elderly, to setting up the Dr. Reddy’s Foundation for Human and Social Development in 1995, Dr. Anji Reddy’s philanthropic endeavours are well-documented. In 1997, an article published in a prominent magazine highlighting India’s abysmal poverty and a widening wealth gap left a lasting impression on him. He identified the lack of opportunity for livelihoods as a major cause of indigence, and encouraged initiatives that would address this need. Programmes such as the Child and Police Project and Livelihood Advancement Business School thrived under his leadership.
By the 1990s, having established a strong presence in APIs, Indian pharma had started to transition its focus towards formulations and finished dosages. Dr. Reddy's led by Dr. Anji Reddy was a key player in this changing landscape. Going up the value chain and entering large regulated markets such as the U.S. became key strategy pillars.
However, it’s his passion for drug discovery that remained his “unfinished agenda”. Dr. Anji Reddy believed that identifying unique opportunities is what will distinguish Dr. Reddy’s Laboratories as a discovery-led company. And this is precisely what we strive to do as a future-forward business dedicated to meeting patients’ unmet needs globally.
Until the end, Dr. Anji Reddy remained true to his passion for drug discovery, to the extent of setting up a separate company using his own funds. It was not only the compulsion of innovation that drove him, but also his conviction that medicines must be affordable.
2
3
4
5
6
7
8
9
0
2
3
4
5
6
7
8
9
0
2
3
4
5
6
7
8
9
0
2
3
4
5
6
7
8
9
0
1985
Our first API factory in Bollaram, Hyderabad, commenced operation.
1986
We went public and were listed on the Bombay Stock Exchange. We launched APIs for the first time in India. In the 1980s, we were among the earliest Indian pharma companies to export APIs to USA at scale.
1991
Our first pioneering mega-brand Omez (Omeprazole) was launched in India, becoming our first 100 crore brand and a leader in Indian pharma.
1992
We expanded our operations internationally by opening a branch in Russia.
1993
We were among earliest in Indian pharma to initiate new drug discovery through the Dr. Reddy’s Research Foundation.
1996
Dr. Anji Reddy founded the Dr. Reddy’s Foundation (DRF) to give back to society. Today, our company’s CSR activities include work in health, education, livelihood and environmental sustainability.
1997
We were the first Indian pharma company to out-license a novel drug to an innovator.
2001
We became the first pharma company in Asia outside Japan to list on the New York Stock Exchange.
We became the first Indian pharma company to obtain a 180-day marketing exclusivity from the USFDA (Fluoxetine capsules 40mg).
Our founder, Dr. Anji Reddy, received the Padma Shri from the Gov’t of India.
We pioneered the concept of 'Self-Managed Teams' to provide skilling and livelihood opportunities to youths around our plant sites.
2002
Aurigene Discovery Technologies Ltd (today, Aurigene Oncology Ltd), our subsidiary in Bengaluru, was incorporated for new drug discovery.
2003
We released our first Safety, Health, Environment (SHE) report. We were also among the earliest to initiate annual voluntary sustainability disclosures from the following year.
2006
We became the fastest Indian pharma company to cross USD 1 billion in revenue.
We became the first Indian pharma company to launch an Authorized Generic (AG) in the U.S. (nasteride 5 mg, generic equivalent of Merck’s Proscar tabs 5 mg).
2007
We launched the world’s then first monoclonal antibody biosimilar of rituximab in India (Reditux).
2010
We launched the world’s then first and India’s only generic of darbepoetin alfa (Cresp) in India.
We adopted 6 sustainability goals for the next decade.
2011
Our founder, Dr. Anji Reddy, was honoured with the Padma Bhushan by the Gov’t of India for his contribution to the Indian pharma industry.
2016
We entered the branded consumer health arena through the acquisition of six OTC brands from Ducere Pharma.
We were listed on the Dow Jones Sustainability Index 2016 for Emerging Markets.
2019
We entered the nutrition segment in India with the launch of Celevida, a first-of-its-kind product in Dr. Reddy’s nutrition portfolio.
We entered the nutraceuticals segment in India with the launch of our diabetes nutrition product, Celevida.
We became the first foreign generics company to receive approval to supply an existing product (Olanzapine) to China's public hospitals under the QCE system.
2020
We became the first company in India and third in Asia to join the Science-Based targets initiative (SBTi).
We acquired select divisions of Wockhardt in India.
We completed #40YearsOfDrReddys on 24th February, 2024.
2020-2021
Our company played its part along with the rest of the pharma industry in the fight against COVID-19.
We combined our in-house efforts with an open-innovation model of partnerships to make available a portfolio that included a vaccine, and therapeutics for mild, moderate and severe COVID-19.
Our focus on agility, access and affordability helped us reach over 5 million patients during the pandemic, especially in low and middle income countries.
2022
Dr. Reddy's Foundation received a National Award from the President of India for the Empowerment of Persons with Disabilities.
Our biggest manufacturing facility in Hyderabad was recognised by the World Economic Forum as part of its Global Lighthouse Network for leadership in the use of Industry 4.0 technologies.
We refreshed our ESG goals to make them bold, measurable, accountable and central to business strategy.
We were named by the prestigious Science Magazine as among the Top 20 employers globally in pharma/biotech. We acquired medical cannabis company, Nimbus Health GmbH, in Germany.
2023
We became the first Indian pharma company to debut on the Dow Jones Sustainability World Index.
We launched Nerivio® in India for migraine management, marking our foray into digital therapeutics.
Our platform ‘Celevida Wellness’ became our first D2C e-commerce platform in India carrying our products for diabetes nutrition and third-party brands.
Our proposed rituximab biosimilar dossier was accepted for review by the USFDA, MHRA and EMA.
We entered into strategic collaborations for novel molecules - with the U.S.-based Coya Therapeutics for a novel combination biologic for ALS; with China-based Junshi Biosciences for Toripalimab; and with Jiangsu Hengrui for Pyrotinib.
We were included in the Bloomberg Gender-Equality Index for the 6th year in a row.
